1. Academic Validation
  2. Comprehensive characterization of TNFSF14/LIGHT with implications in prognosis and immunotherapy of human gliomas

Comprehensive characterization of TNFSF14/LIGHT with implications in prognosis and immunotherapy of human gliomas

  • Front Immunol. 2022 Oct 20;13:1025286. doi: 10.3389/fimmu.2022.1025286.
Mingzhi Han 1 2 3 4 Yanfei Sun 1 Wenbo Zhao 1 Guo Xiang 1 Xu Wang 1 Zheng Jiang 1 Zhiwei Xue 1 Wei Zhou 5
Affiliations

Affiliations

  • 1 Department of Neurosurgery, Qilu Hospital, Cheeloo College of Medicine and Institute of Brain and Brain-Inspired Science, Shandong University, Jinan, China.
  • 2 Jinan Microecological Biomedicine Shandong Laboratory, Jinan, China.
  • 3 Shandong Key Laboratory of Brain Function Remodeling, Jinan, China.
  • 4 Medical Integration and Practice Center, Cheeloo College of Medicine, Shandong University, Jinan, China.
  • 5 Department of Radiation Oncology, Qilu Hospital, Shandong University, Jinan, China.
Abstract

Glioblastoma multiforme (GBM) is a common central neural system malignant tumor among adults. Alongside its microscopic spread, immunosuppression in the tumor microenvironment also induces its refractoriness, which makes immunotherapy for GBM particularly important. Unfortunately, traditional immune checkpoint inhibitors (ICIs) often show limited therapeutic effects in GBM clinical trials, and new therapeutic strategies or targets are urgently needed. TNFSF14/LIGHT is a novel immune checkpoint molecule that plays essential roles in both innate and acquired immunity. Despite recent advances in our understanding of the function of TNFSF14/LIGHT in a variety of Cancer types, the clinical and immunological importance of TNFSF14/LIGHT in human gliomas has not been fully explained. Here, we employed a comprehensive in silico analysis with publicly available data to analyze the molecular and immune characteristics of TNFSF14/LIGHT to explore its feasibility as an immunotherapy target. Totally, 2215 glioma cases were enrolled in the current study. Immunohistochemistry staining based on patient tissues (n = 34) was performed for the validation. TNFSF14/LIGHT was expressed higher in higher-WHO-grade gliomas and mesenchymal subtypes, and it was sensitive as a prognostic marker in GBM and low-grade glioma (LGG). A nomogram prognostic model was established based on TNFSF14/LIGHT expression together with other risk factors. Additionally, Gene Ontology and pathway analysis revealed that TNFSF14/LIGHT participated in T-cell activities and inflammatory processes. Moreover, analysis based on the structure and interactions of TNFSF14/LIGHT revealed its mutation sites in tumors as well as crucial interacting proteins. Analysis of IMvigor210 indicated the role of TNFSF14/LIGHT in immunotherapy. Altogether, our results reveal an underlying role of TNFSF14/LIGHT as an immunotherapy target in GBM.

Keywords

LIGHT; glioma; immune response; prognosis; tumor microenvironment.

Figures